{"classes":[{"categories":[{"measurements":[{"comment":"The median and 95% CIs could not be estimated due to too few events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The median and 95% CIs could not be estimated due to too few events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"226"},{"groupId":"OG001","value":"228"}],"units":"Participants"}],"description":"OS was defined as the time from randomization to the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method. 95% CIs were estimated using the method by Klein and Moeschberger (1997) with log-log transformation. Participants still alive or lost to follow-up or withdrawn consent from study by the analysis time were censored at the date on which the participant was last known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Carfilzomib was administered twice-weekly intravenously as a 10 ± 5 minute infusion using an infusion pump on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycle. The dose was 20 mg/m\\^2 on Days 1 and 2 of Cycle 1 and 27 mg/m\\^2 beginning on Day 8 of Cycle 1 and thereafter. Participants also received lenalidomide 25 mg daily orally on Days 1 to 21 of each cycle and dexamethasone 40 mg weekly orally or intravenously. Participants were treated for up to 12 28-day cycles.","id":"OG000","title":"Twice-weekly KRd 20/27 mg/m^2"},{"description":"Carfilzomib was administered once-weekly intravenously as a 30 ± 5 minute infusion using an infusion pump on Days 1, 8, and 15 of each 28-day cycle. The dose was 20 mg/m\\^2 on Day 1 of Cycle 1 and 56 mg/m\\^2 beginning on Day 8 of Cycle 1 and thereafter. Participants also received lenalidomide 25 mg daily orally on Days 1 to 21 of each cycle and dexamethasone 40 mg weekly orally or intravenously. Participants were treated for up to 12 28-day cycles.","id":"OG001","title":"Once-weekly KRd 20/56 mg/m^2"}],"paramType":"MEDIAN","populationDescription":"The ITT population included all randomized participants.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 up to approximately 12 months (cycle = 28 days); median treatment duration for the twice-weekly arm was 47.00 weeks and for the once-weekly arm was 47.14 weeks.","title":"Kaplan-Meier Estimate of Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}